Phase 1 study of the PARP inhibitor E7449 as a single agent in patients with advanced solid tumors or B-cell lymphoma.

Ruth Plummer; Divyanshu Dua; Nicola Cresti; A. Suder; Yvette Drew; Vasanthi Prathapan; Peter Stephens; Jared K. Thornton; Begoña Bermejo De Las Heras; Barbara Ink; Shannon McGrath; Debashis Sarker

doi:https://doi.org/10.1200/jco.2014.32.15_suppl.e19531

doi.org/10.1200/jco.2014.32.15_suppl.e19531

Phase 1 study of the PARP inhibitor E7449 as a single agent in patients with advanced solid tumors or B-cell lymphoma.

,

,

..., Debashis Sarker

25

Journal of Clinical Oncology45.30

Published: May 20, 2014

Abstract

e19531^ Background: E7449 is an orally bioavailable, likely brain penetrable, potent small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP) 1 and PARP 2 with an IC50 of 1.0 and 1.2 nmol/L...

Paper Fields

Paper Details

Title

Phase 1 study of the PARP inhibitor E7449 as a single agent in patients with advanced solid tumors or B-cell lymphoma.

DOI

doi.org/10.1200/jco.2014.32.15_suppl.e19531

Published Date

May 20, 2014

Journal

Journal of Clinical Oncology

Citation AnalysisPro

You’ll need to upgrade your plan to Pro

Looking to understand the true influence of a researcher’s work across journals & affiliations?

Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.

Learn more

Notes

History